Gilead Remdesivir Production: Partnering, Licensing Concerns And Beximco’s Plans

Gilead has opened up discussions with potential licensing partners, including leading Indian firms, to rapidly scale up supplies of remdesivir, the antiviral that has received FDA emergency use authorization to tackle COVID-19. Healthcare activists say past licensing models used by the US firm are flawed and unacceptable during a global health emergency.

Covid19_Wrecking_Balls — Voluntary licenses for Gilead's remdesivir are in the works

Gilead Sciences Inc. appears to have moved swiftly to ensure that the narrative around production and supplies of remdesivir, the investigational antiviral in the spotlight as a potential treatment for COVID-19, does not trigger any public relations maelstrom or prompt developing nations to target its IPR to ensure access to the therapy.

The US firm outlined a multi-pronged approach to scale up manufacturing and supply of the product. Discussions, it said, were...